What is the 13F Pro Quality Score for IGC?

13F Pro ranks IGC Pharma, Inc. (IGC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IGC's current score at https://13fpro.ai/company/IGC (free sign-up required for the full ranking).

Where does 13F Pro source IGC data?

All IGC Pharma, Inc. fundamentals and ownership data come directly from SEC EDGAR. IGC Pharma, Inc. files with the SEC under CIK 1326205. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IGC in?

IGC Pharma, Inc. (IGC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IGC research updated on 13F Pro?

IGC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

IGC Pharma, Inc.(IGC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSEsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1326205 IGC stock profile & AI dashboard →

13F Pro Quality Score

13.6/100

Rank #2,874 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why IGC Scores 14/100

exact factor attribution · 2026-09-11

IGC's composite is held back by scale and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

-0.8 pts

34th pct

Earnings growth

-2.2 pts

5th pct

Shareholder dilution

-2.3 pts

4th pct

Revenue growth

-2.9 pts

35th pct

Earnings quality

-3.2 pts

18th pct

Capital efficiency

-4.5 pts

5th pct

Profitability

-6.5 pts

6th pct

Free cash flow

-6.7 pts

6th pct

Scale

-7.1 pts

3th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

IGC Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for IGC Pharma, Inc. (IGC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IGC at 13.6/100 on a 32-signal composite quality model, placing it at rank #2,874 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), IGC Pharma, Inc. reports quarterly revenue of $265.0K, net income of $-2.9M, free cash flow of $-2.6M. Top institutional holders of IGC by reported 13-F value include GEODE CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, BlackRock, based on the most recent SEC filings. IGC trades on the NYSE exchange and files with the SEC under CIK 1326205. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IGC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IGC Pharma, Inc. directly from SEC EDGAR. IGC Pharma, Inc.'s 13F Pro composite quality score has ranged between 14 and 25 since 2026, currently 13.6 — a stable long-term trajectory across 8 quarterly and live scoring snapshots.

Revenue

Q2 2026

$265.0K

Net Income

Q2 2026

$-2.9M

Free Cash Flow

Q2 2026

$-2.6M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

—FY 2026

FY23 $911.0KFY24 $1.3MFY25 $1.3MFY26 —

Net Income

—FY 2026

FY23 $-11.5MFY24 $-13.0MFY25 $-7.1MFY26 —

Operating Income

—FY 2026

FY23 $-11.6MFY24 $-9.8MFY25 $-7.4MFY26 —

EPS (Diluted)

—FY 2026

FY23 —FY24 $-0.22FY25 $-0.09FY26 —

Total Assets

+5.0% YoY

$9.2MFY 2026

FY23 $17.2MFY24 $9.9MFY25 $8.7MFY26 $9.2M

Total Debt

—FY 2026

FY23 $144.0KFY24 $140.0KFY25 $137.0KFY26 —

Op. Cash Flow

—FY 2026

FY23 $-7.0MFY24 $-5.2MFY25 $-4.8MFY26 —

Free Cash Flow

—FY 2026

FY23 $-7.4MFY24 $-5.3MFY25 $-4.9MFY26 —

Metric	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	—	$1.3M -5.5%	$1.3M +47.6%	$911.0K +129.5%	$397.0K -55.8%	$898.0K
Net Income	—	$-7.1M +45.2%	$-13.0M -13.0%	$-11.5M +23.4%	$-15.0M -70.4%	$-8.8M
Operating Income	—	$-7.4M +24.0%	$-9.8M +15.3%	$-11.6M +25.0%	$-15.4M -76.8%	$-8.7M
EPS (Diluted)	—	$-0.09 +59.1%	$-0.22	—	—	—
Total Assets	$9.2M +5.0%	$8.7M -11.7%	$9.9M -42.4%	$17.2M -36.0%	$26.8M -25.2%	$35.9M
Total Debt	—	$137.0K -2.1%	$140.0K -2.8%	$144.0K -2.0%	$147.0K -74.7%	$580.0K
Operating Cash Flow	—	$-4.8M +7.8%	$-5.2M +26.2%	$-7.0M +5.6%	$-7.5M +30.9%	$-10.8M
Free Cash Flow	—	$-4.9M +8.1%	$-5.3M +27.5%	$-7.4M +4.4%	$-7.7M +37.3%	$-12.3M

Get alerted when IGC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for IGC Pharma, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IGC

GEODE CAPITAL MANAGEMENT, LLC
$239.2K879,394 sh
VANGUARD CAPITAL MANAGEMENT LLC
$221.7K814,914 sh
BlackRock, Inc.
$191.4K703,798 sh
AdvisorShares Investments LLC
$184.5K678,480 sh
CITADEL ADVISORS LLC
$119.0K437,317 sh
VANGUARD FIDUCIARY TRUST CO
$114.1K419,413 sh
RENAISSANCE TECHNOLOGIES LLC
$78.0K286,608 sh
STATE STREET CORP
$54.6K200,799 sh
NORTHERN TRUST CORP
$46.3K170,274 sh
LAWOOD & CO
$20.4K75,000 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$239.2K	879,394
VANGUARD CAPITAL MANAGEMENT LLC	$221.7K	814,914
BlackRock, Inc.	$191.4K	703,798
AdvisorShares Investments LLC	$184.5K	678,480
CITADEL ADVISORS LLC	$119.0K	437,317
VANGUARD FIDUCIARY TRUST CO	$114.1K	419,413
RENAISSANCE TECHNOLOGIES LLC	$78.0K	286,608
STATE STREET CORP	$54.6K	200,799
NORTHERN TRUST CORP	$46.3K	170,274
LAWOOD & CO	$20.4K	75,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IGC on your watchlist

Track score changes the day IGC Pharma, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IGC a good stock to buy?

13F Pro's AI-powered analysis of IGC Pharma, Inc. (IGC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IGC are available on the IGC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. IGC is classified as a small company.

Which hedge funds own IGC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IGC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of IGC Pharma, Inc.'s investment landscape.